CCP
FOLD

Cardan Capital Partners’s Amicus Therapeutics FOLD Stock Holding History

Cardan Capital Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-378,141
Closed -$8.73M – 246
2020
Q4 		$8.73M Buy
+378,141
New +$7.73M 1.08% 24

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cardan Capital Partners's FOLD Position: Q1 2021 in Review

Cardan Capital Partners sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 378,141 shares — an estimated $8.73M sold.

Cardan Capital Partners first reported a position in FOLD in Q4 2020 and held it in 1 quarter. The position peaked at $8.73M in Q4 2020. 259 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

  • Cardan Capital Partners reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Cardan Capital Partners sold 378,141 Amicus Therapeutics shares in Q1 2021, an estimated $8.73M.
  • Cardan Capital Partners first reported a position in Amicus Therapeutics in Q4 2020 and held it in 1 quarter.
  • Cardan Capital Partners's Amicus Therapeutics position peaked at $8.73M in Q4 2020.
  • 259 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Cardan Capital Partners's 13F filing for Q1 2021, filed 13 Apr 2021.